Boston Scientific Revenue 2012-2025 | BSX
Boston Scientific annual/quarterly revenue history and growth rate from 2012 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Boston Scientific revenue for the quarter ending September 30, 2025 was $5.065B, a 20.34% increase year-over-year.
- Boston Scientific revenue for the twelve months ending September 30, 2025 was $19.351B, a 21.63% increase year-over-year.
- Boston Scientific annual revenue for 2024 was $16.747B, a 17.61% increase from 2023.
- Boston Scientific annual revenue for 2023 was $14.24B, a 12.29% increase from 2022.
- Boston Scientific annual revenue for 2022 was $12.682B, a 6.68% increase from 2021.
|
Boston Scientific Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $16,747 |
| 2023 | $14,240 |
| 2022 | $12,682 |
| 2021 | $11,888 |
| 2020 | $9,913 |
| 2019 | $10,735 |
| 2018 | $9,823 |
| 2017 | $9,048 |
| 2016 | $8,386 |
| 2015 | $7,477 |
| 2014 | $7,380 |
| 2013 | $7,143 |
| 2012 | $7,249 |
| 2011 | $7,622 |
|
Boston Scientific Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2025-09-30 | $5,065 |
| 2025-06-30 | $5,061 |
| 2025-03-31 | $4,663 |
| 2024-12-31 | $4,562 |
| 2024-09-30 | $4,209 |
| 2024-06-30 | $4,120 |
| 2024-03-31 | $3,856 |
| 2023-12-31 | $3,725 |
| 2023-09-30 | $3,527 |
| 2023-06-30 | $3,599 |
| 2023-03-31 | $3,389 |
| 2022-12-31 | $3,242 |
| 2022-09-30 | $3,170 |
| 2022-06-30 | $3,244 |
| 2022-03-31 | $3,026 |
| 2021-12-31 | $3,127 |
| 2021-09-30 | $2,932 |
| 2021-06-30 | $3,077 |
| 2021-03-31 | $2,752 |
| 2020-12-31 | $2,708 |
| 2020-09-30 | $2,659 |
| 2020-06-30 | $2,003 |
| 2020-03-31 | $2,543 |
| 2019-12-31 | $2,904 |
| 2019-09-30 | $2,707 |
| 2019-06-30 | $2,631 |
| 2019-03-31 | $2,493 |
| 2018-12-31 | $2,561 |
| 2018-09-30 | $2,393 |
| 2018-06-30 | $2,490 |
| 2018-03-31 | $2,379 |
| 2017-12-31 | $2,409 |
| 2017-09-30 | $2,222 |
| 2017-06-30 | $2,257 |
| 2017-03-31 | $2,160 |
| 2016-12-31 | $2,191 |
| 2016-09-30 | $2,105 |
| 2016-06-30 | $2,126 |
| 2016-03-31 | $1,964 |
| 2015-12-31 | $1,978 |
| 2015-09-30 | $1,888 |
| 2015-06-30 | $1,843 |
| 2015-03-31 | $1,768 |
| 2014-12-31 | $1,887 |
| 2014-09-30 | $1,846 |
| 2014-06-30 | $1,873 |
| 2014-03-31 | $1,774 |
| 2013-12-31 | $1,838 |
| 2013-09-30 | $1,735 |
| 2013-06-30 | $1,809 |
| 2013-03-31 | $1,761 |
| 2012-12-31 | $1,820 |
| 2012-09-30 | $1,735 |
| 2012-06-30 | $1,828 |
| 2012-03-31 | $1,866 |
| 2011-12-31 | $1,848 |
| 2011-09-30 | $1,874 |
| 2011-06-30 | $1,975 |
| 2011-03-31 | $1,925 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $144.746B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $218.959B | 25.23 |
| EssilorLuxottica (ESLOY) | France | $150.458B | 0.00 |
| Stryker (SYK) | United States | $140.556B | 27.91 |
| Medtronic (MDT) | Ireland | $125.035B | 17.32 |
| Medline (MDLN) | United States | $53.232B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.704B | 0.00 |
| Agilent Technologies (A) | United States | $42.105B | 26.62 |
| GE HealthCare Technologies (GEHC) | United States | $39.758B | 19.01 |
| ResMed (RMD) | United States | $36.846B | 25.50 |
| Koninklijke Philips (PHG) | Netherlands | $28.483B | 18.60 |
| Terumo (TRUMY) | Japan | $21.735B | 24.47 |
| Insulet (PODD) | United States | $20.333B | 63.11 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.401B | 11.48 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.263B | 0.00 |
| Baxter (BAX) | United States | $10.831B | 8.74 |
| Sunny Optical Technology (SNPTF) | China | $9.589B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.735B | 31.41 |
| Demant (WILYY) | Denmark | $7.372B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $4.480B | 13.65 |
| BillionToOne (BLLN) | United States | $3.933B | 0.00 |
| Envista Holdings (NVST) | United States | $3.885B | 22.29 |
| Haemonetics (HAE) | United States | $3.840B | 17.09 |
| ICU Medical (ICUI) | United States | $3.777B | 23.98 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.099B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.086B | 14.07 |
| QuidelOrtho (QDEL) | United States | $2.286B | 14.69 |
| Neogen (NEOG) | United States | $2.093B | 45.81 |
| Perrigo (PRGO) | Ireland | $2.075B | 5.20 |
| AtriCure (ATRC) | United States | $2.061B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.928B | 38.81 |
| Curaleaf Holdings (CURLF) | Canada | $1.716B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.680B | 73.64 |
| Phibro Animal Health (PAHC) | United States | $1.599B | 15.97 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.577B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.425B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.421B | 20.57 |
| BioLife Solutions (BLFS) | United States | $1.197B | 355.14 |
| Capricor Therapeutics (CAPR) | United States | $1.090B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.031B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.005B | 0.00 |
| InMode (INMD) | Israel | $0.913B | 10.31 |
| Omeros (OMER) | United States | $0.886B | 0.00 |
| CeriBell (CBLL) | United States | $0.865B | 0.00 |
| Valneva SE (VALN) | France | $0.850B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.563B | 15.26 |
| Verano Holdings (VRNO) | United States | $0.461B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.453B | 0.00 |
| Brainsway (BWAY) | Israel | $0.453B | 77.03 |
| Cresco Labs (CRLBF) | United States | $0.443B | 0.00 |
| SNDL (SNDL) | Canada | $0.436B | 0.00 |
| Cerus (CERS) | United States | $0.396B | 0.00 |
| Quanterix (QTRX) | United States | $0.376B | 0.00 |
| Evolus (EOLS) | United States | $0.366B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.290B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.275B | 21.94 |
| Sanuwave Health (SNWV) | United States | $0.266B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.242B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.240B | 141.00 |
| High Tide (HITI) | Canada | $0.234B | 0.00 |
| Organigram Global (OGI) | Canada | $0.232B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.217B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Vireo Growth (VREOF) | United States | $0.208B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.192B | 16.92 |
| Accendra Health (ACH) | United States | $0.190B | 1.91 |
| OraSure Technologies (OSUR) | United States | $0.189B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.154B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.145B | 0.00 |
| Exagen (XGN) | United States | $0.144B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.137B | 0.00 |
| Apyx Medical (APYX) | United States | $0.133B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.118B | 0.00 |
| Biote (BTMD) | United States | $0.118B | 5.16 |
| MacroGenics (MGNX) | United States | $0.116B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.71 |
| ImmuCell (ICCC) | United States | $0.059B | 24.98 |
| Sharps Technology (STSS) | United States | $0.055B | 0.00 |
| Nephros (NEPH) | United States | $0.051B | 37.00 |
| Cytosorbents (CTSO) | United States | $0.042B | 0.00 |
| Jin Medical (ZJYL) | China | $0.039B | 0.00 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Modular Medical (MODD) | United States | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.029B | 14.53 |
| Allurion Technologies (ALUR) | United States | $0.016B | 0.00 |
| Bonk (BNKK) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.013B | 0.00 |
| INLIF (INLF) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| Flora Growth (FLGC) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Agape ATP (ATPC) | $0.004B | 0.00 | |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |